Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Neulasta (pegfilgrastim by Year
Neulasta (pegfilgrastim — Febrile Neutropenia) — U.S. product sales ($M) ($M)
Amgen Neulasta (pegfilgrastim: $359M in FY2025, up 12.9% from a year earlier.
Latest, FY2025
359
Period ended Dec 31, 2025
Change on a year earlier
+12.9%
318 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Neulasta — U.S. | 359 | 13 | % | 318 | (55) | % | 710”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neulasta (pegfilgrastim — Febrile Neutropenia) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 359 | +12.9% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 318 | -55.2% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 710 | -26.0% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 959 | -36.7% | Form 10-K (filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 1,514 | -24.3% | Form 10-K (filed 2023-02-09) ↗ |
| FY2020 | Dec 31, 2020 | 2,001 | -28.9% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 2,814 | -27.2% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 3,866 | -1.7% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 3,931 | +0.2% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 3,925 | – | Form 10-K (filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Neulasta (pegfilgrastim ($M), annual FY2016–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-neulasta-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.